您的位置: 首页 > 农业专利 > 详情页

Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
专利权人:
AgonOx, Inc.;Providence Health & Services - Oregon
发明人:
Weinberg, Andrew, D.,Montler, Ryan,Duhen, Thomas,Duhen, Rebekka
申请号:
AU2018281830
公开号:
AU2018281830A1
申请日:
2018.05.04
申请国别(地区):
AU
年份:
2019
代理人:
摘要:
Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充